Loss to Follow-up After Intravitreal Anti–Vascular Endothelial Growth Factor Injections in Patients with Diabetic Macular Edema
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (3) , 230-236
Abstract
No abstract availableKeywords
Funding Information
- Allergan
- Santen
This publication has 22 references indexed in Scilit:
- Barriers to Eye Care Among People Aged 40 Years and Older With Diagnosed Diabetes, 2006–2010Diabetes Care, 2013
- Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFUJournal of Clinical Epidemiology, 2013
- The Association Between Compliance With Recommended Follow-up and Glaucomatous Disease Severity in a County Hospital PopulationAmerican Journal of Ophthalmology, 2013
- Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real lifeGraefe's Archive for Clinical and Experimental Ophthalmology, 2012
- Anti–Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular EdemaOphthalmology, 2012
- Current Epidemiology of Diabetic Retinopathy and Diabetic Macular EdemaCurrent Diabetes Reports, 2012
- The worldwide epidemic of diabetic retinopathyIndian Journal Of Ophthalmology, 2012
- Noncompliance with Vision Care Guidelines in Latinos with Type 2 Diabetes MellitusOphthalmology, 2006
- Perceived Barriers to Diabetic Eye CareArchives of Ophthalmology (1950), 2005
- The Cosine-Haversine FormulaThe American Mathematical Monthly, 1957